To determine cost-utility of interferons intramuscular beta-1-a (IFN?-1a-IM), subcutaneous beta-1-a (IFN?-1a-SC), subcutaneous beta-1-b (IFN?-1b-SC) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in Colombia. Methods: The base case patient has a RRMS severity < 2.5 according to Expanded Disability Status Scale, the perspective of analysis was from Colombian health system. Time horizon was 20 years; the annual discount rate was 5% for benefits and costs. Outcomes: proportion of patients without relapses during 24 months, survival rate at 20 years, Quality-Adjusted Life Years (QALYs). Direct costs were calculated for the year 2015. A Markov decision model was constructed in a hypothetical cohort of 1000 patients, considering ten disease’ states. The model represents the probabilities of moving from state to state, leaving the treatment and dying